NCT07768345
A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 17 → 21 locations
- Minor Trial sites expanded: 10 → 17 locations
- Notable Eligibility criteria expanded, about 10 words
- Trial sites expanded: 5 → 10 locations
- Notable Recruitment opened
- Trial sites expanded: 1 → 5 locations
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Percentage of participants reporting local reactions
Timeframe: For up to 7 days after vaccination
Percentage of participants reporting systemic events
Timeframe: For up to 7 days after vaccination
Percentage of participants reporting adverse events
Timeframe: Through 1 month after vaccination
Percentage of participants reporting newly diagnosed chronic medical conditions
Timeframe: Through 12 months after vaccination
Percentage of participants reporting serious adverse events
Timeframe: Through 12 months after vaccination
Neutralizing Titers (NTs) for RSV A and RSV B expressed as Geometric Mean Titer (GMT)
Timeframe: Before vaccination, 1 month, 6 months and 12 months after vaccination
NTs for RSV A and RSV B expressed as Geometric Mean Fold Rise (GMFR)
Timeframe: Before vaccination, 1 month, 6 months and 12 months after vaccination
Secondary (1)
Seroresponse rate of NTs for RSV A and RSV B
Arms and interventions
Group 1Experimental
RSVpreF Vaccine
Group 2Experimental
RSVpreF Vaccine
Group 3Experimental
RSVpreF Vaccine
Group 4Experimental
RSVpreF Vaccine
Biologicals: RSVpreF Vaccine
Sites
21 sites in 1 country